https://orcid.org/0000-0002-7692-2189
References
- Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377(2):162–172.
- Chiò A, Hammond ER, Mora G, et al. Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2015;86(1):38–44.
- Corcia P, Beltran S, Lautrette G, et al. Staging amyotrophic lateral sclerosis: a new focus on progression. Rev Neurol. 2019;175(5):277–282.
- Tramacere I, Dalla Bella E, Chiò A, et al. The MITOS system predicts long-term survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2015;86(11):1180–1185.
- Lechtzin N, Cudkowicz ME, de Carvalho M, et al. Respiratory measures in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19(5-6):321–330.
- Hartmaier SL, Rhodes T, Cook SF, et al. Qualitative measures that assess functional disability and quality of life in ALS. Health Qual Life Outcomes. 2022;20(1):12.
- Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS study group (phase III). J Neurol Sci. 1999;169(1-2):13–21.
- Shefner JM, Andrews JA, Genge A, et al. A phase 2, double-blind, randomized, dose-ranging trial of reldesemtiv in patients with ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2021;22(3-4):287–299.
- Moore A, Young CA, Hughes DA. Mapping ALSFRS-R and ALSUI to EQ-5D in patients with motor neuron disease. Value Health. 2018;21(11):1322–1329.
- Devlin NJ, Shah KK, Feng Y, et al. Valuing health-related quality of life: an EQ-5D-5L value set for England. Health Econ. 2018;27(1):7–22.
- Detry MA, Ma Y. Analyzing repeated measurements using mixed models. JAMA. 2016;315(4):407–408.
- Griffiths A, Paracha N, Davies A, et al. Analyzing health-related quality of life data to estimate parameters for cost-effectiveness models: an example using longitudinal EQ-5D data from the SHIFT randomized controlled trial. Adv Ther. 2017;34(3):753–764.
- Matthews JN, Altman DG, Campbell MJ, et al. Analysis of serial measurements in medical research. BMJ. 1990;300(6719):230–235.
- Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ. 2005;14(5):487–496.
- Xin Y, Ashburn A, Pickering RM, et al. Cost-effectiveness of the PDSAFE personalised physiotherapy intervention for fall prevention in Parkinson’s: an economic evaluation alongside a randomised controlled trial. BMC Neurol. 2020;20(1):295.
- National Institute for Health and Care Excellence. Position statement on use of the EQ-5D-5L value set for England (updated October 2019) [Internet]. 2019 [accessed 2022 July 8]. Available from: https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/technology-appraisal-guidance/eq-5d-5l
- Institute for Clinical and Economic Review. Value assessment framework [Internet]. 2020 [accessed 2022 July 8]. Available from: https://icer.org/our-approach/methods-process/value-assessment-framework/
- Coretti S, Ruggeri M, McNamee P. The minimum clinically important difference for EQ-5D index: a critical review. Expert Rev Pharmacoecon Outcomes Res. 2014;14(2):221–233.
- Goldfeld KS, Hamel MB, Mitchell SL. The cost-effectiveness of the decision to hospitalize nursing home residents with advanced dementia. J Pain Symptom Manage. 2013;46(5):640–651.
- Polak TB, Cucchi DGJ, Darrow JJ, et al. Incremental benefits of novel pharmaceuticals in the UK: a cross-sectional analysis of NICE technology appraisals from 2010 to 2020. BMJ Open. 2022;12(4):e058279.
- Makam AN, Suh K, Nikitin D, et al. AMX0035 and oral edaravone for ALS; final evidence report [Internet]. Institute for Clinical and Economic Review. 2022 Sept 1 [ accessed 2023 Jan 11]. Available from: https://icer.org/assessment/amyotrophic-lateral-sclerosis-2022/#timeline
- EuroQol Research Foundation. New UK EQ-5D-5L valuation study [Internet]. 2022 [accessed 2022 July 8]. Available from: https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/valuation-standard-value-sets/new-uk-eq-5d-5l-valuation-study_blog/